Lung Density Analysis vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Lung Density Analysis

by IMBIO

EchoNext

by Pathway Labs

AI Verdict

IMBIO's Lung Density Analysis focuses on providing quantitative analysis and 3D visualization of lung conditions from CT scans, primarily for diseases like COPD and emphysema. In contrast, Pathway Labs' EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. While both are AI-powered diagnostic tools in cardiology, their distinct input data (CT scans vs. ECGs) and primary focus areas (lung conditions vs. structural heart disease) make them adjacent rather than direct competitors.

Choose Lung Density Analysis if…

Choose Imbio's Lung Density Analysis if your practice focuses on pulmonology or radiology and requires detailed, quantitative analysis of lung conditions from CT scans. It is particularly well-suited for lung cancer screening programs, assessing COPD and emphysema severity, and guiding smoking cessation counseling with its patient-centered LungMap™ report. The tool offers automated detection, visualization, and quantification of emphysema, even on low-dose CT scans.

View Lung Density Analysis →

Choose EchoNext if…

Choose EchoNext if your practice aims to enhance early detection of hidden structural heart disease using standard ECGs. This AI tool is ideal for cardiologists, family medicine, hospital medicine, and internal medicine specialists looking to screen for conditions like heart failure, valve disease, and pulmonary hypertension, potentially before symptoms present. It can help identify patients who warrant further evaluation with an echocardiogram, thereby improving diagnostic accuracy and potentially reducing unnecessary advanced imaging.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Lung Density Analysis	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Cloud-based, Locally virtualized (VM, Docker), Integration in PACS, AI marketplace/distribution platforms, Stand-alone web-based.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung Density Analysis

IMBIO's Lung Density Analysis emphasizes automated workflows and detailed, patient-centered reports, including a LungMapu2122 report for smoking cessation counseling, which suggests a focus on ease of use and actionable insights for both clinicians and patients. EchoNext is integrated into the OpenEvidence platform, which is used by many physicians, suggesting good accessibility, but less is explicitly stated about its direct user experience or reporting features beyond its diagnostic capabilities.

Clinical Value

EchoNext

EchoNext has demonstrated superior diagnostic accuracy compared to cardiologists in identifying structural heart disease from ECGs, even when cardiologists were assisted by AI. It was trained on over 700,000 ECG-echocardiogram pairs and validated across multiple hospital systems, with a peer-reviewed case showing it guided a patient to a heart transplant. IMBIO's Lung Density Analysis provides quantitative analysis of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema, and is validated for low-dose CT scans.

Pricing & Value

EchoNext

EchoNext provides transparent tiered pricing starting at $600/month, with details on different plans and potential discounts. IMBIO's Lung Density Analysis requires contacting them for pricing, with no public disclosure of costs, making it difficult to assess its value proposition without direct inquiry.

Enterprise Readiness

Lung Density Analysis

IMBIO's Lung Density Analysis offers flexible deployment options including cloud-based, locally virtualized, integration with PACS, and AI marketplaces, indicating robust enterprise readiness. EchoNext is available through the OpenEvidence clinical decision support platform, which is a strong integration point, but its deployment flexibility beyond that platform is not as clearly articulated.

Innovation

EchoNext

EchoNext is highlighted as the world's first FDA-approved AI detection tool to analyze ECGs for hidden structural heart disease, a novel application that can transform routine ECGs into a screening tool for serious cardiac conditions. IMBIO's Lung Density Analysis offers advanced quantitative analysis and 3D visualization of lung conditions, including patented technology for mapping lung components, which is innovative in its domain but less of a 'first-of-its-kind' breakthrough compared to EchoNext.

Support & Docs

Tie

Both tools are FDA-cleared and HIPAA compliant, suggesting a baseline level of documentation and adherence to standards. However, specific details regarding ongoing customer support, training programs, or the breadth and accessibility of their documentation are not extensively detailed for either product in the provided information or web searches.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Lung Density Analysis	EchoNext
Name	Lung Density Analysis	EchoNext
Company	IMBIO	Pathway Labs
Description	IMBIO's Lung Density Analysis is an AI-driven medical imaging software that provides quantitative analysis and 3D visualization of lung conditions from CT scans, aiding in the diagnosis and management of diseases like COPD and emphysema. It offers automated workflows and detailed reports for personalized patient care.	EchoNext is an FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Specialties	Pulmonology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring Lung Density Analysis and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

IMBIO's Lung Density Analysis offers flexible deployment options including cloud-based, locally virtualized, and integration into PACS or AI marketplaces, aiming for fully automated solutions that deliver quantitative analysis and 3D visualization to the patient study in PACS. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by many U.S. clinicians, allowing its screening output to be directly accessible within a platform physicians may already use, rather than requiring a separate system or workflow.

What is the accuracy and sensitivity of each tool in detecting relevant clinical conditions?

IMBIO's Lung Density Analysis provides reproducible CT values for pulmonary tissue and is validated for low-dose CT scans in lung cancer screening, offering quantitative support for diagnosis and follow-up. EchoNext has demonstrated high accuracy in detecting structural heart disease, achieving an AUROC of 85% in internal tests and 78-80% in external validation, and in studies, it has shown higher accuracy (77%) compared to cardiologists (64%) in identifying structural heart problems from ECGs.

What is the learning curve for physicians and what kind of support is available for each tool?

IMBIO's Lung Density Analysis is designed as a fully automated solution, aiming to reduce additional work for radiologists and provide patient-friendly reports, suggesting a lower learning curve for interpretation. EchoNext is integrated into the OpenEvidence platform, which is already used by many clinicians, potentially reducing the learning curve as physicians would access the tool within a familiar environment.

Beyond HIPAA, what additional security features or protocols are in place to protect patient data?

The provided information does not detail security features beyond HIPAA compliance for either Tool A (IMBIO Lung Density Analysis) or Tool B (EchoNext). Both tools are stated to be HIPAA compliant.

What audit-trail features are available to track the use and impact of the AI analysis?

The provided information does not specify audit-trail features for either IMBIO's Lung Density Analysis or EchoNext.

How do these tools support multi-site rollouts and consistent application across different clinical settings?

IMBIO's Lung Density Analysis has been deployed in multi-site lung cancer screening programs, indicating its capability for consistent application across various sites. EchoNext has shown consistent performance across diverse patient demographics, clinical contexts, and numerous hospitals, with validation studies spanning over 20 hospitals and 500,000 patients in the U.S. and Canada, suggesting suitability for multi-site rollouts.

In what specific clinical contexts would each tool be most beneficial for a physician?

IMBIO's Lung Density Analysis is particularly beneficial for pulmonologists and radiologists in diagnosing and managing COPD, emphysema, asthma, and bronchiolitis obliterans, especially when pulmonary function tests are inconclusive, and for surgical planning or lung cancer screening programs. EchoNext is valuable for cardiologists, family medicine, and hospital medicine physicians as a screening tool to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs, especially for early detection before symptoms present.